BofA Securities maintained a Buy rating on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) with a price target of DKK1,075.00. The firm's analyst commented on the stock's recent performance, noting ...
Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...
Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback